Successful second-line treatment with cabozantinib for hepatocellular carcinoma harboring cytoplasmic mesenchymal-epithelial transition factor amplification.

MLA

Yamamoto, Makoto, et al. “Successful Second-Line Treatment with Cabozantinib for Hepatocellular Carcinoma Harboring Cytoplasmic Mesenchymal-Epithelial Transition Factor Amplification.” Hepatology Research : The Official Journal of the Japan Society of Hepatology, vol. 54, no. 3, Mar. 2024, pp. 315–19. EBSCOhost, https://doi.org/10.1111/hepr.13975.

APA

Yamamoto, M., Terashima, T., Yamashita, T., Seki, A., Nakagawa, H., Nio, K., Shimakami, T., Takatori, H., Arai, K., Mizukoshi, E., Honda, M., Takeuchi, S., & Yamashita, T. (2024). Successful second-line treatment with cabozantinib for hepatocellular carcinoma harboring cytoplasmic mesenchymal-epithelial transition factor amplification. Hepatology Research : The Official Journal of the Japan Society of Hepatology, 54(3), 315–319. https://doi.org/10.1111/hepr.13975

Chicago

Yamamoto, Makoto, Takeshi Terashima, Tatsuya Yamashita, Akihiro Seki, Hidetoshi Nakagawa, Kouki Nio, Tetsuro Shimakami, et al. 2024. “Successful Second-Line Treatment with Cabozantinib for Hepatocellular Carcinoma Harboring Cytoplasmic Mesenchymal-Epithelial Transition Factor Amplification.” Hepatology Research : The Official Journal of the Japan Society of Hepatology 54 (3): 315–19. doi:10.1111/hepr.13975.